A Phase 2 interventional study of Setmelanotide and Placebo in Genetic Obesity, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 36 sites in 8 countries. Open to participants aged 6 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-02.
Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing setmelanotide in Obesity — 1 open to participants now, 2 under way, none of them phase 3. setmelanotide · Obesity.
Among the 16 studies testing setmelanotide in Obesity, this one is the 4th largest by enrollment, is the only one that started in 2021, is one of 6 in phase 2, and was the 12th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →1 of the 16 studies testing setmelanotide in Obesity is open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
By country, each count listing its studies:
setmelanotide: first FDA approval 2020 (IMCIVREE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 6 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 7
First in 2012; this study’s year is marked. 1 started in 2021.
This study's enrollment of 164 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 34 across the 16 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 16 have an industry lead sponsor. The 2 most frequent:
Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
19 studies in Obesity by Rhythm Pharmaceuticals, Inc.: none open now, 2 under way, none of them phase 3. Of 16 finished, 10 (63%) have results posted.
Among the 19 studies in Obesity by Rhythm Pharmaceuticals, Inc., this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2021, is one of 5 in phase 2, and was the 14th registered.
Rhythm Pharmaceuticals, Inc.’s Obesity studies by the year they started, since 2012.
1 of the studies testing setmelanotide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496463Massachusetts General HospitalSetmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a) | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing setmelanotide in Obesity, from their registry updates:
Among Rhythm Pharmaceuticals, Inc.’s 19 in Obesity:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the safety and efficacy of once daily subcutaneous (SC) administration of setmelanotide in participants with obesity and specific gene variants in the MC4R pathway.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria applied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received once daily SC injection of setmelanotide from Day 1 to Week 16 in an open-label treatment stage (Stage 1). Participants ≥12 years of age started on setmelanotide 2.0 milligrams (mg) once daily for approximately 2 weeks, then increased to 3.0 mg once daily. Participants \<12 years of age started on setmelanotide 1.0 mg once daily for approximately 1 week, then increased to 2.0 mg once daily for approximately 1 week, then increased to 3.0 mg once daily.
Drug: Setmelanotide
Participants from Stage 1 who were eligible for Stage 2 received once daily SC injection of setmelanotide 3.0 mg from Week 16 to Week 40 in a double-blind treatment Stage (Stage 2).
Drug: Setmelanotide
Participants from Stage 1 who were eligible for Stage 2 received once daily SC injection of matching placebo 3.0 mg from Week 16 to Week 40 in a double-blind treatment Stage (Stage 2).
Drug: Placebo
SC injection
SC injection
Stage 1: Number of Participants by Genotype Who Demonstrated a Significant Clinically Meaningful Response to Setmelanotide at the End of Stage 1
BMI was calculated using participant's weight and height assessments, using the following formula: BMI = Kilogram (kg)/ square meter (m\^2). A significant clinically meaningful response was defined as achieving a ≥5% reduction in BMI from Baseline. Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.
Time frame: Baseline to Week 16
Mean Change in BMI From Baseline to the End of Stage 1 in All Participants, Per Genotype
BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.
Time frame: Baseline, Week 16
Mean Change in BMI From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype
BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2 Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.
Time frame: Baseline, Week 16
Percent Change in BMI From Baseline to the End of Stage 1 in All Participants, Per Genotype
BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2 Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.
Time frame: Baseline, Week 16
Percent Change in BMI From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype
BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2 Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.
Time frame: Baseline, Week 16
Mean Change in Body Weight From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype
Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.
Time frame: Baseline, Week 16
Percent Change in Body Weight From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype
Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.
Time frame: Baseline, Week 16
Mean Change in BMI Z-score From Baseline to the End of Stage 1 in Participants <18 Years Old, Per Genotype
BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-score indicated the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score indicates a reduction in BMI from Baseline whereas an increase of BMI-Z score indicates an increase in BMI from Baseline. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.
Time frame: Baseline, Week 16
Percent Change in the Weekly Average of the Daily Maximal Hunger Score From Baseline to the End of Stage 1 in Participants ≥12 Years Old, Per Genotype
Daily Hunger Questionnaire for participants ≥12 years of age is self-administered questionnaire and comprises three items. For the assessment of this endpoint, maximal hunger was corresponding to the following question: In the last 24 hours, how hungry did you feel when you were the most hungry? The response was scored separately and averaged on weekly basis. Participants rated their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all, and 10 = hungriest possible). Weekly average at Week 16 was defined as average of the available score values within 7 days in Week 16. Baseline was defined as the average of the available score values within 7 days before or on the stage 1 open-label treatment. Results are reported by overall participant results and by specific gene cohort.
Time frame: Baseline, Week 16
Number of Participants ≥12 Years Old, Who Achieved a ≥2 Point Reduction From Baseline to the End of Stage 1 in the Weekly Average of the Daily Maximal Hunger Score, Per Genotype
Daily Hunger Questionnaire for participants ≥12 years of age is self-administered questionnaire and comprises three items. For the assessment of this endpoint, maximal hunger was corresponding to the following question: In the last 24 hours, how hungry did you feel when you were the most hungry? The response was scored separately and averaged on weekly basis. Participants rated their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all, and 10 = hungriest possible). Weekly average at Week 16 was defined as average of the available score values within 7 days in Week 16. Baseline was defined as the average of the available score values within 7 days before or on the stage 1 open-label treatment. Results are reported by overall participant results and by specific gene cohort.
Time frame: Baseline, Week 16
| Milestone | Stage 1: Setmelanotide (Open-Label) | Stage 2: Setmelanotide (Double-Blind) | Stage 2: Placebo (Double-Blind) |
|---|---|---|---|
| Started | 164 | 0 | 0 |
| Completed | 100 | 0 | 0 |
| Not completed | 64 | 0 | 0 |
| Withdrew: Adverse event | 43 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 16 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
| Milestone | Stage 1: Setmelanotide (Open-Label) | Stage 2: Setmelanotide (Double-Blind) | Stage 2: Placebo (Double-Blind) |
|---|---|---|---|
| Started | 0 | 32 | 17 |
| Safety analysis set enrolled in stage 2 | 0 | 35 | 14 |
| Completed | 0 | 29 | 10 |
| Not completed | 0 | 3 | 7 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 | 2 |
| Withdrew: Other than specified | 0 | 1 | 4 |
BMI was calculated using participant's weight and height assessments, using the following formula: BMI = Kilogram (kg)/ square meter (m\^2). A significant clinically meaningful response was defined as achieving a ≥5% reduction in BMI from Baseline. Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.
| Participants | Stage 1: Setmelanotide (Open-Label) |
|---|---|
| Overall | 49 |
| Gene: NRP1 | 0 |
| Gene: NRP2 | 0 |
| Gene: PLXNA1 | 2 |
| Gene: PLXNA2 | 3 |
| Gene: PLXNA3 | 2 |
| Gene: PLXNA4 | 5 |
| Gene: SEMA3A | 2 |
| Gene: SEMA3B | 1 |
| Gene: SEMA3C | 0 |
| Gene: SEMA3D | 0 |
| Gene: SEMA3E | 3 |
| Gene: SEMA3F | 2 |
| Gene: SEMA3G | 8 |
| Gene: PHIP | 9 |
| Gene: SIM1 | 5 |
| Gene: MAGEL2 | 3 |
| Gene: CREBBP | 0 |
| Gene: DNMT3A | 0 |
| Gene: HTR2C | 0 |
| Gene: KSR2 | 1 |
| Gene: MRAP2 | 0 |
| Gene: RPGRIP1L | 1 |
| Gene: TBX3 | 2 |
| Gene: TRPC5 | 0 |
BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.
| Kg/m^2 | Stage 1: Setmelanotide (Open-Label) |
|---|---|
| Overall: At Baseline | 45.338 ± 9.5526 |
| Overall: Change at Week 16 | -1.916 ± 1.7971 |
| Gene: NRP1, At Baseline | 48.601 ± 2.7893 |
| Gene: NRP1, Change at Week 16 | 0.229 ± 1.6024 |
| Gene: NRP2, At Baseline | 46.568 ± 10.6754 |
| Gene: NRP2, Change at Week 16 | -1.040 ± 0.8650 |
| Gene: PLXNA1, At Baseline | 45.576 ± 5.5644 |
| Gene: PLXNA1, Change at Week 16 | -1.884 ± 1.8912 |
| Gene: PLXNA2, At Baseline | 48.577 ± 12.1795 |
| Gene: PLXNA2, Change at Week 16 | -2.492 ± 2.0273 |
| Gene: PLXNA3, At Baseline | 34.083 ± 6.4705 |
| Gene: PLXNA3, Change at Week 16 | -3.333 ± 0.5166 |
| Gene: PLXNA4, At Baseline | 46.634 ± 8.5714 |
| Gene: PLXNA4, Change at Week 16 | -2.218 ± 2.9947 |
| Gene: SEMA3A, At Baseline | 39.405 ± 7.8242 |
| Gene: SEMA3A, Change at Week 16 | -2.328 ± 0.2612 |
| Gene: SEMA3B, At Baseline | 42.890 ± 5.0100 |
| Gene: SEMA3B, Change at Week 16 | -2.557 |
| Gene: SEMA3C, At Baseline | 47.543 |
| Gene: SEMA3C, Change at Week 16 | -2.334 |
| Gene: SEMA3D, At Baseline | 45.814 ± 5.7690 |
| Gene: SEMA3D, Change at Week 16 | -1.638 ± 0.6445 |
| Gene: SEMA3E, At Baseline | 43.005 ± 1.6275 |
| Gene: SEMA3E, Change at Week 16 | -3.132 ± 2.4180 |
| Gene: SEMA3F, At Baseline | 54.979 ± 15.1825 |
| Gene: SEMA3F, Change at Week 16 | -3.556 ± 1.1758 |
| Gene: SEMA3G, At Baseline | 44.464 ± 8.4848 |
| Gene: SEMA3G, Change at Week 16 | -2.124 ± 1.5203 |
| Gene: PHIP, At Baseline | 40.808 ± 10.0222 |
| Gene: PHIP, Change at Week 16 | -2.120 ± 1.0108 |
| Gene: SIM1, At Baseline | 47.729 ± 9.7294 |
| Gene: SIM1, Change at Week 16 | -1.698 ± 1.8931 |
| Gene: MAGEL2, At Baseline | 42.047 ± 8.2605 |
| Gene: MAGEL2, Change at Week 16 | -1.637 ± 1.3549 |
| Gene: CREBBP, At Baseline | 47.490 |
| Gene: CREBBP, Change at Week 16 | 0.165 |
| Gene: DNMT3A, At Baseline | 44.138 |
| Gene: DNMT3A, Change at Week 16 | -1.080 |
| Gene: HTR2C, At Baseline | 52.105 ± 3.0212 |
| Gene: HTR2C, Change at Week 16 | -1.381 |
| Gene: KSR2, At Baseline | 47.624 ± 11.4457 |
| Gene: KSR2, Change at Week 16 | -1.073 ± 1.4410 |
| Gene: MRAP2, At Baseline | 58.100 |
| Gene: MRAP2, Change at Week 16 | -1.470 |
| Gene: RPGRIP1L, At Baseline | 43.442 ± 2.6778 |
| Gene: RPGRIP1L, Change at Week 16 | -3.603 |
| Gene: TBX3, At Baseline | 40.170 ± 10.5867 |
| Gene: TBX3, Change at Week 16 | -1.951 ± 1.3582 |
| Gene: TRPC5, At Baseline | 49.974 ± 24.5155 |
| Gene: TRPC5, Change at Week 16 | 0.161 ± 1.2979 |
BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2 Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.
| Kg/m^2 | Stage 1: Setmelanotide (Open-Label) |
|---|---|
| Overall: At Baseline | 48.464 ± 8.0877 |
| Overall: Change at Week 16 | -1.872 ± 1.8963 |
| Gene: NRP2, At Baseline | 51.640 ± 8.5762 |
| Gene: NRP2, Change at Week 16 | -0.783 ± 1.0489 |
| Gene: PLXNA1, At Baseline | 46.959 ± 6.2279 |
| Gene: PLXNA1, Change at Week 16 | -0.678 ± 0.8796 |
| Gene: PLXNA2, At Baseline | 50.335 ± 12.3004 |
| Gene: PLXNA2, Change at Week 16 | -2.324 ± 0.6565 |
| Gene: PLXNA3, At Baseline | 40.801 |
| Gene: PLXNA3, Change at Week 16 | -3.698 |
| Gene: PLXNA4, At Baseline | 48.420 ± 7.4340 |
| Gene: PLXNA4, Change at Week 16 | -2.532 ± 3.1514 |
| Gene: SEMA3A, At Baseline | 47.366 |
| Gene: SEMA3A, Change at Week 16 | -2.513 |
| Gene: SEMA3B, At Baseline | 43.320 |
| Gene: SEMA3D, At Baseline | 47.296 ± 6.0613 |
| Gene: SEMA3D, Change at Week 16 | -1.638 ± 0.6445 |
| Gene: SEMA3E, At Baseline | 42.004 ± 1.1954 |
| Gene: SEMA3E, Change at Week 16 | -4.716 ± 0.0565 |
| Gene: SEMA3F, At Baseline | 64.964 ± 9.9946 |
| Gene: SEMA3F, Change at Week 16 | -4.388 |
| Gene: SEMA3G, At Baseline | 46.762 ± 6.5047 |
| Gene: SEMA3G, Change at Week 16 | -2.302 ± 1.6478 |
| Gene: PHIP, At Baseline | 45.343 ± 7.0089 |
| Gene: PHIP, Change at Week 16 | -2.110 ± 1.1464 |
| Gene: SIM1, At Baseline | 50.790 ± 8.9593 |
| Gene: SIM1, Change at Week 16 | -1.465 ± 1.7916 |
| Gene: MAGEL2, At Baseline | 46.198 ± 5.0997 |
| Gene: MAGEL2, Change at Week 16 | -1.191 ± 1.0137 |
| Gene: CREBBP, At Baseline | 47.490 |
| Gene: CREBBP, Change at Week 16 | 0.165 |
| Gene: DNMT3A, At Baseline | 44.138 |
| Gene: DNMT3A, Change at Week 16 | -1.080 |
| Gene: HTR2C, At Baseline | 52.105 ± 3.0212 |
| Gene: HTR2C, Change at Week 16 | -1.381 |
| Gene: KSR2, At Baseline | 51.397 ± 9.2011 |
| Gene: KSR2, Change at Week 16 | -0.792 ± 1.5759 |
| Gene: RPGRIP1L, At Baseline | 43.442 ± 2.6778 |
| Gene: RPGRIP1L, Change at Week 16 | -3.603 |
| Gene: TBX3, At Baseline | 44.494 ± 4.3444 |
| Gene: TBX3, Change at Week 16 | -0.705 |
| Gene: TRPC5, At Baseline | 62.246 ± 17.2758 |
| Gene: TRPC5, Change at Week 16 | 0.161 ± 1.2979 |
BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2 Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.
| percent change | Stage 1: Setmelanotide (Open-Label) |
|---|---|
| Overall: Change at Week 16 | -4.62 ± 4.394 |
| Gene: NRP1, Change at Week 16 | 0.57 ± 3.329 |
| Gene: PLXNA1, Change at Week 16 | -4.00 ± 4.296 |
| Gene: NRP2, Change at Week 16 | -2.33 ± 2.105 |
| Gene: PLXNA2, Change at Week 16 | -4.90 ± 3.909 |
| Gene: PLXNA3, Change at Week 16 | -8.95 ± 0.156 |
| Gene: PLXNA4, Change at Week 16 | -5.00 ± 6.577 |
| Gene: SEMA3A, Change at Week 16 | -5.39 ± 0.123 |
| Gene: SEMA3B, Change at Week 16 | -6.79 |
| Gene: SEMA3C, Change at Week 16 | -4.91 |
| Gene: SEMA3D, Change at Week 16 | -3.57 ± 1.960 |
| Gene: SEMA3E, Change at Week 16 | -7.39 ± 5.752 |
| Gene: SEMA3F, Change at Week 16 | -7.66 ± 0.119 |
| Gene: SEMA3G, Change at Week 16 | -5.09 ± 3.284 |
| Gene: PHIP, Change at Week 16 | -6.12 ± 3.623 |
| Gene: SIM1, Change at Week 16 | -4.02 ± 5.310 |
| Gene: MAGEL2, Change at Week 16 | -4.60 ± 4.288 |
| Gene: CREBBP, Change at Week 16 | 0.35 |
| Gene: DNMT3A, Change at Week 16 | -2.45 |
| Gene: HTR2C, Change at Week 16 | -2.49 |
| Gene: KSR2, Change at Week 16 | -2.15 ± 2.928 |
| Gene: MRAP2, Change at Week 16 | -2.53 |
| Gene: RPGRIP1L, Change at Week 16 | -8.64 |
| Gene: TBX3, Change at Week 16 | -6.41 ± 5.011 |
| Gene: TRPC5, Change at Week 16 | -0.03 ± 2.094 |
BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2 Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.
| percent change | Stage 1: Setmelanotide (Open-Label) |
|---|---|
| Overall: Change at Week 16 | -3.95 ± 4.057 |
| Gene: NRP2, Change at Week 16 | -1.37 ± 1.804 |
| Gene: PLXNA1, Change at Week 16 | -1.22 ± 1.576 |
| Gene: PLXNA2, Change at Week 16 | -4.69 ± 0.913 |
| Gene: PLXNA3, Change at Week 16 | -9.06 |
| Gene: PLXNA4, Change at Week 16 | -5.34 ± 6.682 |
| Gene: SEMA3A, Change at Week 16 | -5.31 |
| Gene: SEMA3D, Change at Week 16 | -3.57 ± 1.960 |
| Gene: SEMA3E, Change at Week 16 | -11.23 ± 0.185 |
| Gene: SEMA3F, Change at Week 16 | -7.58 |
| Gene: SEMA3G, Change at Week 16 | -4.80 ± 2.810 |
| Gene: PHIP, Change at Week 16 | -5.11 ± 2.770 |
| Gene: SIM1, Change at Week 16 | -2.63 ± 3.720 |
| Gene: MAGEL2, Change at Week 16 | -2.67 ± 2.227 |
| Gene: CREBBP, Change at Week 16 | 0.35 |
| Gene: DNMT3A, Change at Week 16 | -2.45 |
| Gene: HTR2C, Change at Week 16 | -2.49 |
| Gene: KSR2, Change at Week 16 | -1.23 ± 3.189 |
| Gene: RPGRIP1L, Change at Week 16 | -8.64 |
| Gene: TBX3, Change at Week 16 | -1.70 |
| Gene: TRPC5, Change at Week 16 | -0.03 ± 2.094 |
Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.
| Kg | Stage 1: Setmelanotide (Open-Label) |
|---|---|
| Overall, At Baseline | 136.01 ± 29.815 |
| Overall: Change at Week 16 | -5.33 ± 5.315 |
| Gene: NRP2, At Baseline | 147.35 ± 2.098 |
| Gene: NRP2, Change at Week 16 | -2.03 ± 2.687 |
| Gene: PLXNA1, At Baseline | 145.30 ± 33.751 |
| Gene: PLXNA1, Change at Week 16 | -2.33 ± 3.144 |
| Gene: PLXNA2, At Baseline | 137.94 ± 37.878 |
| Gene: PLXNA2, Change at Week 16 | -6.50 ± 2.234 |
| Gene: PLXNA3, At Baseline | 89.73 |
| Gene: PLXNA3, Change at Week 16 | -8.13 |
| Gene: PLXNA4, At Baseline | 135.87 ± 24.052 |
| Gene: PLXNA4, Change at Week 16 | -7.55 ± 8.772 |
| Gene: SEMA3A, At Baseline | 157.07 |
| Gene: SEMA3A, Change at Week 16 | -8.33 |
| Gene: SEMA3B, At Baseline | 97.60 |
| Gene: SEMA3D, At Baseline | 128.09 ± 49.981 |
| Gene: SEMA3D, Change at Week 16 | -4.48 ± 0.589 |
| Gene: SEMA3E, At Baseline | 115.77 ± 19.328 |
| Gene: SEMA3E, Change at Week 16 | -12.98 ± 1.956 |
| Gene: SEMA3F, At Baseline | 176.65 ± 10.960 |
| Gene: SEMA3F, Change at Week 16 | -12.80 |
| Gene: SEMA3G, At Baseline | 129.41 ± 21.874 |
| Gene: SEMA3G, Change at Week 16 | -6.59 ± 4.622 |
| Gene: PHIP, At Baseline | 134.11 ± 36.996 |
| Gene: PHIP, Change at Week 16 | -5.77 ± 3.504 |
| Gene: SIM1, At Baseline | 141.25 ± 35.591 |
| Gene: SIM1, Change at Week 16 | -4.13 ± 4.720 |
| Gene: MAGEL2, At Baseline | 134.41 ± 20.544 |
| Gene: MAGEL2, Change at Week 16 | -3.88 ± 3.681 |
| Gene: CREBBP, At Baseline | 103.60 |
| Gene: CREBBP, Change at Week 16 | 0.36 |
| Gene: DNMT3A, At Baseline | 129.37 |
| Gene: DNMT3A, Change at Week 16 | -3.17 |
| Gene: HTR2C, At Baseline | 126.23 ± 9.780 |
| Gene: HTR2C, Change at Week 16 | -3.40 |
| Gene: KSR2, At Baseline | 150.16 ± 19.630 |
| Gene: KSR2, Change at Week 16 | -2.13 ± 4.721 |
| Gene: RPGRIP1L, At Baseline | 103.47 ± 11.193 |
| Gene: RPGRIP1L, Change at Week 16 | -8.63 |
| Gene: TBX3, At Baseline | 119.00 ± 11.644 |
| Gene: TBX3, Change at Week 16 | -2.17 |
| Gene: TRPC5, At Baseline | 203.00 ± 25.173 |
| Gene: TRPC5, Change at Week 16 | 0.20 ± 4.243 |
Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.
| percent change | Stage 1: Setmelanotide (Open-Label) |
|---|---|
| Overall: Change at Week 16 | -3.94 ± 4.052 |
| Gene: NRP2, Change at Week 16 | -1.37 ± 1.804 |
| Gene: PLXNA1, Change at Week 16 | -1.22 ± 1.576 |
| Gene: PLXNA2, Change at Week 16 | -4.69 ± 0.913 |
| Gene: PLXNA3, Change at Week 16 | -9.06 |
| Gene: PLXNA4, Change at Week 16 | -5.34 ± 6.682 |
| Gene: SEMA3A, Change at Week 16 | -5.31 |
| Gene: SEMA3D, Change at Week 16 | -3.57 ± 1.960 |
| Gene: SEMA3E, Change at Week 16 | -11.23 ± 0.185 |
| Gene: SEMA3F, Change at Week 16 | -7.58 |
| Gene: SEMA3G, Change at Week 16 | -4.80 ± 2.810 |
| Gene: PHIP, Change at Week 16 | -5.00 ± 2.749 |
| Gene: SIM1, Change at Week 16 | -2.63 ± 3.720 |
| Gene: MAGEL2, Change at Week 16 | -2.67 ± 2.227 |
| Gene: CREBBP, Change at Week 16 | 0.35 |
| Gene: DNMT3A, Change at Week 16 | -2.45 |
| Gene: HTR2C, Change at Week 16 | -2.49 |
| Gene: KSR2, Change at Week 16 | -1.23 ± 3.189 |
| Gene: RPGRIP1L, Change at Week 16 | -8.64 |
| Gene: TBX3, Change at Week 16 | -1.70 |
| Gene: TRPC5, Change at Week 16 | -0.03 ± 2.094 |
BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-score indicated the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score indicates a reduction in BMI from Baseline whereas an increase of BMI-Z score indicates an increase in BMI from Baseline. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.
| z-score | Stage 1: Setmelanotide (Open-Label) |
|---|---|
| Overall, At Baseline | 2.649 ± 0.3708 |
| Overall: Change at Week 16 | -0.126 ± 0.1425 |
| Gene: NRP1, At Baseline | 2.919 ± 0.0848 |
| Gene: NRP1, Change at Week 16 | -0.000 ± 0.0124 |
| Gene: NRP2, At Baseline | 2.386 |
| Gene: NRP2, Change at Week 16 | -0.086 |
| Gene: PLXNA1, At Baseline | 2.729 ± 0.1250 |
| Gene: PLXNA1, Change at Week 16 | -0.112 ± 0.0671 |
| Gene: PLXNA2, At Baseline | 2.955 ± 0.0601 |
| Gene: PLXNA2, Change at Week 16 | -0.043 ± 0.0707 |
| Gene: PLXNA3, At Baseline | 2.485 ± 0.4970 |
| Gene: PLXNA3, Change at Week 16 | -0.234 |
| Gene: PLXNA4, At Baseline | 2.693 ± 0.3653 |
| Gene: PLXNA4, Change at Week 16 | -0.063 ± 0.1110 |
| Gene: SEMA3A, At Baseline | 2.498 ± 0.2057 |
| Gene: SEMA3A, Change at Week 16 | -0.078 |
| Gene: SEMA3B, At Baseline | 2.595 ± 0.5201 |
| Gene: SEMA3B, Change at Week 16 | -0.140 |
| Gene: SEMA3C, At Baseline | 2.828 |
| Gene: SEMA3C, Change at Week 16 | -0.037 |
| Gene: SEMA3D, At Baseline | 2.454 |
| Gene: SEMA3E, At Baseline | 2.913 ± 0.4705 |
| Gene: SEMA3E, Change at Week 16 | -0.053 ± 0.0808 |
| Gene: SEMA3F, At Baseline | 2.847 ± 0.5676 |
| Gene: SEMA3F, Change at Week 16 | -0.192 |
| Gene: SEMA3G, At Baseline | 2.826 ± 0.4890 |
| Gene: SEMA3G, Change at Week 16 | -0.115 ± 0.1020 |
| Gene: PHIP, At Baseline | 2.457 ± 0.4515 |
| Gene: PHIP, Change at Week 16 | -0.201 ± 0.1923 |
| Gene: SIM1, At Baseline | 2.510 ± 0.3107 |
| Gene: SIM1, Change at Week 16 | -0.182 ± 0.2355 |
| Gene: MAGEL2, At Baseline | 2.503 ± 0.3034 |
| Gene: MAGEL2, Change at Week 16 | -0.184 ± 0.1615 |
| Gene: MRAP2, At Baseline | 2.738 |
| Gene: MRAP2, Change at Week 16 | -0.019 |
| Gene: KSR2, At Baseline | 2.831 ± 0.2260 |
| Gene: KSR2, Change at Week 16 | -0.037 ± 0.0131 |
| Gene: TBX3, At Baseline | 2.471 ± 0.4419 |
| Gene: TBX3, Change at Week 16 | -0.254 ± 0.1661 |
| Gene: TRPC5, At Baseline | 2.078 |
Daily Hunger Questionnaire for participants ≥12 years of age is self-administered questionnaire and comprises three items. For the assessment of this endpoint, maximal hunger was corresponding to the following question: In the last 24 hours, how hungry did you feel when you were the most hungry? The response was scored separately and averaged on weekly basis. Participants rated their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all, and 10 = hungriest possible). Weekly average at Week 16 was defined as average of the available score values within 7 days in Week 16. Baseline was defined as the average of the available score values within 7 days before or on the stage 1 open-label treatment. Results are reported by overall participant results and by specific gene cohort.
| percent change | Stage 1: Setmelanotide (Open-Label) |
|---|---|
| Overall: Change at Week 16 | -31.13 ± 63.273 |
| Gene: NRP2, Change at Week 16 | -39.63 ± 1.203 |
| Gene: PLXNA1, Change at Week 16 | -21.04 ± 10.064 |
| Gene: PLXNA2, Change at Week 16 | -44.12 ± 37.973 |
| Gene: PLXNA3, Change at Week 16 | -49.25 ± 4.785 |
| Gene: PLXNA4, Change at Week 16 | -54.61 ± 31.759 |
| Gene: SEMA3A, Change at Week 16 | -15.35 ± 5.880 |
| Gene: SEMA3B, Change at Week 16 | -15.79 |
| Gene: SEMA3C, Change at Week 16 | 0.00 |
| Gene: SEMA3D, Change at Week 16 | 36.36 |
| Gene: SEMA3E, Change at Week 16 | -37.37 ± 23.609 |
| Gene: SEMA3F, Change at Week 16 | -48.16 ± 24.821 |
| Gene: SEMA3G, Change at Week 16 | 38.70 ± 176.373 |
| Gene: PHIP, Change at Week 16 | -56.87 ± 19.460 |
| Gene: SIM1, Change at Week 16 | -25.60 ± 51.690 |
| Gene: MAGEL2, Change at Week 16 | -39.44 ± 30.215 |
| Gene: DNMT3A, Change at Week 16 | -23.00 |
| Gene: HTR2C, Change at Week 16 | -37.29 |
| Gene: KSR2, Change at Week 16 | -42.17 ± 30.842 |
| Gene: MRAP2, Change at Week 16 | -47.83 |
| Gene: RPGRIP1L, Change at Week 16 | -100.00 |
| Gene: TBX3, Change at Week 16 | -33.67 ± 2.720 |
| Gene: TRPC5, Change at Week 16 | -16.82 ± 28.427 |
Daily Hunger Questionnaire for participants ≥12 years of age is self-administered questionnaire and comprises three items. For the assessment of this endpoint, maximal hunger was corresponding to the following question: In the last 24 hours, how hungry did you feel when you were the most hungry? The response was scored separately and averaged on weekly basis. Participants rated their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all, and 10 = hungriest possible). Weekly average at Week 16 was defined as average of the available score values within 7 days in Week 16. Baseline was defined as the average of the available score values within 7 days before or on the stage 1 open-label treatment. Results are reported by overall participant results and by specific gene cohort.
| Participants | Stage 1: Setmelanotide (Open-Label) |
|---|---|
| Overall | 49 |
| Gene: NRP2 | 2 |
| Gene: PLXNA1 | 1 |
| Gene: PLXNA2 | 3 |
| Gene: PLXNA3 | 2 |
| Gene: PLXNA4 | 6 |
| Gene: SEMA3A | 0 |
| Gene: SEMA3B | 0 |
| Gene: SEMA3C | 0 |
| Gene: SEMA3D | 0 |
| Gene: SEMA3E | 2 |
| Gene: SEMA3F | 2 |
| Gene: SEMA3G | 4 |
| Gene: PHIP | 7 |
| Gene: SIM1 | 7 |
| Gene: MAGEL2 | 5 |
| Gene: CREBBP | 0 |
| Gene: DNMT3A | 0 |
| Gene: HTR2C | 1 |
| Gene: KSR2 | 3 |
| Gene: MRAP2 | 0 |
| Gene: RPGRIP1L | 1 |
| Gene: TBX3 | 2 |
| Gene: TRPC5 | 1 |
Collected over Stage 1 : Baseline to Week 16 Stage 2 : Week 16 to Week 44. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage 1: Setmelanotide (Open-Label) | 0/164 (0%) | 6/164 (3.7%) | 160/164 (97.6%) |
| Stage 2: Setmelanotide (Double-Blind) | 0/35 (0%) | 0/35 (0%) | 25/35 (71.4%) |
| Stage 2: Placebo (Double-Blind) | 0/14 (0%) | 0/14 (0%) | 10/14 (71.4%) |
| Event | Stage 1: Setmelanotide (Open-Label) | Stage 2: Setmelanotide (Double-Blind) | Stage 2: Placebo (Double-Blind) |
|---|---|---|---|
| DepressionPsychiatric disorders | 2/164 | 0/35 | 0/14 |
| GastritisGastrointestinal disorders | 1/164 | 0/35 | 0/14 |
| VomitingGastrointestinal disorders | 1/164 | 0/35 | 0/14 |
| HeadacheNervous system disorders | 1/164 | 0/35 | 0/14 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/164 | 0/35 | 0/14 |
| AngioedemaSkin and subcutaneous tissue disorders | 1/164 | 0/35 | 0/14 |
| Event | Stage 1: Setmelanotide (Open-Label) | Stage 2: Setmelanotide (Double-Blind) | Stage 2: Placebo (Double-Blind) |
|---|---|---|---|
| Skin hyperpigmentationSkin and subcutaneous tissue disorders | 130/164 | 7/35 | 1/14 |
| NauseaGastrointestinal disorders | 75/164 | 4/35 | 0/14 |
| Injection site erythemaGeneral disorders | 62/164 | 1/35 | 2/14 |
| Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 52/164 | 7/35 | 2/14 |
| Injection site pruritusGeneral disorders | 49/164 | 1/35 | 0/14 |
| Injection site indurationGeneral disorders | 47/164 | 1/35 | 2/14 |
| Injection site painGeneral disorders | 46/164 | 0/35 | 1/14 |
| HeadacheNervous system disorders | 43/164 | 4/35 | 0/14 |
| VomitingGastrointestinal disorders | 41/164 | 3/35 | 0/14 |
| FatigueGeneral disorders | 29/164 | 0/35 | 1/14 |
Safety Analysis Set included all participants who received at least one dose of trial medication.
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 30.2 ± 16.94 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 110 |
| Male | 54 |
| Ethnicity (NIH/OMB)(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 38 |
| Not Hispanic or Latino | 124 |
| Unknown or Not Reported | 2 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 2 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 16 |
| White | 128 |
| More than one race | 0 |
| Unknown or Not Reported | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2021 to primary completion in Aug 2023, 20 months.
Results were first posted in Oct 2024, 1 year 2 months after primary completion.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 20 months is above that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Setmelanotide
Rhythm Pharmaceuticals, Inc. →